## **Prostaglandin E2-d4**

Cat. No.:	HY-101952S	
CAS No.:	34210-10-1	D D O
Molecular Formula:	$C_{20}H_{28}D_{4}O_{5}$	о С ОН
Molecular Weight:	356.49	L D D
Target:	Prostaglandin Receptor; Endogenous Metabolite	
Pathway:	GPCR/G Protein; Metabolic Enzyme/Protease	HO
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.	HÔ

BIOLOGICAL ACTIVITY		
IC <sub>50</sub> & Target	EP	
In Vitro	Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	

## REFERENCES

[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.

[2]. Chouaib S, et al. The mechanisms of inhibition of human IL 2 production. II. PGE2 induction of suppressor T lymphocytes. J Immunol. 1984 Apr;132(4):1851-7.

[3]. Fernandez-Repollet E, et al. In vivo effects of prostaglandin E2 and arachidonic acid on phagocytosis of fluorescent methacrylate microbeads by rat peritoneal macrophages. J Histochem Cytochem. 1982 May;30(5):466-70.

[4]. Haylor J, et al. Renal vasodilator activity of prostaglandin E2 in the rat anaesthetized with pentobarbitone. Br J Pharmacol. 1982 May;76(1):131-7.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

**Product** Data Sheet



Page 1 of 1